HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
01 avr. 2024 16h10 HE
|
HCW Biologics, Inc
Q4 and Year End Earnings Release and Business Highlights
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
14 nov. 2023 07h00 HE
|
HCW Biologics, Inc
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
08 nov. 2023 07h30 HE
|
HCW Biologics, Inc
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
01 nov. 2023 07h30 HE
|
HCW Biologics, Inc
Masonic Cancer Center, University of Minnesota to Present Human Data Readout for HCW9218 Phase 1 Study at SITC 2023
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
06 sept. 2023 07h30 HE
|
HCW Biologics, Inc
MIRAMAR, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
11 août 2023 07h00 HE
|
HCW Biologics, Inc
MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
14 juin 2023 07h30 HE
|
HCW Biologics, Inc
MIRAMAR, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights
09 mai 2023 07h15 HE
|
HCW Biologics, Inc
MIRAMAR, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing...
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
27 avr. 2023 07h40 HE
|
HCW Biologics, Inc
Provides funding for buildout of new headquarters and manufacturing facility Capital requirements now funded into 2025 MIRAMAR, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the...
HCW Biologics Poster Presentation at AACR Annual Meeting 2023
13 avr. 2023 07h15 HE
|
HCW Biologics, Inc
Presentation of data for the mechanism underlying HCW9218 against solid tumors HCW9218 is the clinical-stage, lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., April 13, 2023 (GLOBE...